From the utility of annual TB testing for patients on biologics, the safety of vaccines during treatment, and the use of advanced therapeutics during pregnancy to monitoring protocols for patients on Janus kinase (JAK) and Tyrosine Kinase 2 (TYK2) inhibitors, Mona Shahriari, MD covers it all in this overview of her talk from the 2025 Diversity in Dermatology Meeting in Louisville, KY. Dr. Shahriari is an Assistant Clinical Professor of Dermatology at Yale University School of Medicine in New Haven, CT, and the Associate Director of Clinical Trials at Central Connecticut Dermatology (CCD) Research.
